
|Articles|July 1, 2002
PCa supplement found tainted, pulled from the market
Orlando, FL-Just as researchers were beginning to quantify the value of PC-SPES in treating advanced prostate cancer, the product was found to be contaminated, was taken off the market, and the manufacturer went out of business.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
Individualizing androgen pathway therapy in mCSPC
4
BOND-003 Cohort C: Efficacy Results
5








